Last reviewed · How we verify
Peginterferon alfa-2a plus Tenofovir
Peginterferon alfa-2a plus Tenofovir is a Small molecule drug developed by Ruijin Hospital. It is currently FDA-approved. Also known as: Pegasys;TDF.
At a glance
| Generic name | Peginterferon alfa-2a plus Tenofovir |
|---|---|
| Also known as | Pegasys;TDF |
| Sponsor | Ruijin Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection (PHASE2)
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (PHASE2)
- Impact of Fatty Liver on Hepatitis B Therapy
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (PHASE2)
- A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection (PHASE2)
- HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon alfa-2a plus Tenofovir CI brief — competitive landscape report
- Peginterferon alfa-2a plus Tenofovir updates RSS · CI watch RSS
- Ruijin Hospital portfolio CI
Frequently asked questions about Peginterferon alfa-2a plus Tenofovir
What is Peginterferon alfa-2a plus Tenofovir?
Peginterferon alfa-2a plus Tenofovir is a Small molecule drug developed by Ruijin Hospital.
Who makes Peginterferon alfa-2a plus Tenofovir?
Peginterferon alfa-2a plus Tenofovir is developed and marketed by Ruijin Hospital (see full Ruijin Hospital pipeline at /company/ruijin-hospital).
Is Peginterferon alfa-2a plus Tenofovir also known as anything else?
Peginterferon alfa-2a plus Tenofovir is also known as Pegasys;TDF.
What development phase is Peginterferon alfa-2a plus Tenofovir in?
Peginterferon alfa-2a plus Tenofovir is FDA-approved (marketed).
Related
- Manufacturer: Ruijin Hospital — full pipeline
- Also known as: Pegasys;TDF
- Compare: Peginterferon alfa-2a plus Tenofovir vs similar drugs
- Pricing: Peginterferon alfa-2a plus Tenofovir cost, discount & access